Title

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

Authors

Leonard Moise, University of Rhode IslandFollow
Anthony Marcello
Ryan Tassone, University of Rhode IslandFollow
Leslie Cousens
William Martin
Anne S. De Groot, University of Rhode IslandFollow

Document Type

Article

Date of Original Version

2013

Abstract

EpiVax, Inc., is an early-stage informatics and immunology biotechnology company in Providence, Rhode Island. It applies computational tools to harness immunity in three major areas: immunomodulation, biotherapeutic immunogenicity risk assessment and de-risking, and vaccine development. Immunotherapy, bio-better and vaccine candidates under development at EpiVax promise to improve the health outcomes of millions of people affected by devastating immune-related diseases.

Citation/Publisher Attribution

Moise, L., Marcello, A., Tassone, R., Cousens, L., Martin, W., & De Groot, A. S. (2013). Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., Immunology Company. Rhode Island Medical Journal, 1(96),19-21.

Available at: http://rimed.org/rimedicaljournal/2013/02/2013-02-19-bio-epivax.pdf